Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (June 2026)
20 slides from Argenica Therapeutics's investor presentation, June 2026
Slide 1: Precision Neuroprotection for Severe Brain Injury
Precision Neuroprotection for Severe Brain Injury ARGENICA THERAPEUTICS Targeting patients where brain injury – and value – is greatest INVESTOR PRESENTATION - ASX:AGN JUNE 2026 DR LIZ DALLIMORE - MANAGING DIRECTOR PRESENTATION 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Investment Overview
INVESTMENT OVERVIEW PRECISION NEUROPROTECTION APPROACH TO SEVERE BRAIN INJURY SCIENTIFICALLY VALIDATED FIRST-IN-CLASS NEUROPROTECTIVE DRUG Xaranetide (ARG-007) is a neuroprotective therapy targeting acute and secondary brain injury, with extensive preclinical efficacy data published on the ability o
Slide 4: Key Company Metrics
KEY COMPANY METRICS $8M $15M FY26 CASH @ BANK 1 MARKET CAP2 R&D Tax Rebate Expected H2 ARGENICA THERAPEUTICS 128.5M 37% SHARES HELD BY TOP 20 +ve DATA SHARES ON ISSUE IN PHASE 2 STROKE TRIAL 1. Cash balance as @ 31 March 2026 4 2. Calculated with closing price on @ 10th April 2026 being $0.11 www.ar
Slide 5: Ischaemic Stroke Opportunity
ISCHAEMIC STROKE ARGENICA THERAPEUTICS OPPORTUNITY 5 www.argenica.com.au
Slide 6: Stroke Has the Greatest Incidence of Disability and Death of All Neurological Conditions
STROKE HAS THE GREATEST INCIDENCE OF DISABILITY AND DEATH OF ALL NEUROLOGICAL CONDITIONS1 • Stroke is the leading neurological cause of long-term disability and death, significantly greater than other leading neurological conditions. • Stroke-related costs in the United States came to nearly $56.5 b
Slide 7: This Represents a Huge Unmet Need
Number of stroke victims each year globally 1 THIS REPRESENTS A HUGE UNMET NEED 5m 4.5m 4m ~5 MILLION PEOPLE AIS Drug Treatment market valued at $10.6 Billion by 2027 1. suffering from an acute ischaemic stroke globally each year1 3.5m Current standard of care treatments for more severe stroke ARGEN
Slide 8: ARG-007's Unique Mechanism of Action to Reduce Multiple Causes of Brain Injury
ARG-007’S UNIQUE MECHANISM OF ACTION TO REDUCE MULTIPLE CAUSES OF BRAIN INJURY ARGENICA THERAPEUTICS 8 Values in graphic approximated from Edwards et al., Mol Brain 2018 11(1):8 and Chiu et al., 2020. Curr Ther Res Clin Exp. 19:92:100584 for illustrative purposes www.argenica.com.au
Slide 9: Phase 2 Trial Results
PHASE 2 TRIAL ARGENICA THERAPEUTICS RESULTS 9 www.argenica.com.au
Slide 10: Phase 2 Trial Design and Patient Pathway
PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of Endpoints patients to meet inclusion 0.3mg/kg ARG-007 or Mortality rate and frequency of Adverse and Serious criteria saline place
Slide 11: The Phase 2 trial identified a treatment effect in more severe stroke patients
The Phase 2 trial identified a treatment effect in more severe stroke patients, paving the way for a precision-designed Phase 2b trial PHASE 2 POST HOC RESULTS • Whilst no overall effect was seen across the broader patient group due to baseline stroke severity imbalance ARGENICA THERAPEUTICS and ina
Slide 12: ARG-007 significantly reduces growth of damaged brain in moderate to severe stroke patients
ARG-007 significantly reduces growth of damaged brain in moderate to severe stroke patients ARGENICA THERAPEUTICS Figure 1: Total corrected ischaemic lesion volumes (cISC) in ml as predicted from the corresponding multivariate model across different baseline AIV values (0ml, 10ml, 20ml; 30 ml). The
Slide 13: Moderate to severe stroke patients have reduced disability following ARG-007 treatment
Moderate to severe stroke patients have reduced disability following ARG-007 treatment ARGENICA THERAPEUTICS Figure 2: In multivariate analysis there was a significant interaction between infarct core size and treatment effect on clinical outcomes, specifically the modified rankin scale. Patients wi
Slide 14: ARG-007 significantly improved disability outcomes in patients with more severe strokes
ARG-007 significantly improved disability outcomes in patients with more severe strokes ABLE TO WALK WITHOUT ASSISTANCE ARGENICA THERAPEUTICS Figure 3: Distribution of the mRS at 90 days across treatment arms using e-ASPECTS or AIV to exclude patients with small infarct cores alongside patients with
Slide 15: FDA Clinical Hold Update
FDA CLINICAL HOLD UPDATE The three safety assays requested by the FDA are now complete, with ARG-007 showing a clean safety profile across all three assays. Comprehensive clinical hold response to be submitted to FDA within weeks. FDA-Requested Assay Status Outcome Tenecteplase (TNK) Drug-Drug Inter
Slide 16: Phase 2b Trial: Designed to Prove Efficacy in Moderate to Severe Strokes
PHASE 2b TRIAL: DESIGNED TO PROVE EFFICACY IN MODERATE TO SEVERE STROKES Moderate to severe stroke (ASPECTS 3-8, AI assisted interpretation) PATIENT Large Vessel Occlusion undergoing thrombectomy POPULATION With or without thrombolysis ARGENICA THERAPEUTICS mRS shift 90 days ENDPOINT mRS 0
Slide 17: Clinical Advisory Committee to Drive Phase 2b Trial
CLINICAL ADVISORY COMMITTEE TO DRIVE PHASE 2B TRIAL Dr Tim Phillips Prof Geoffrey Donnan Dr Jeffery Saver Neurointerventionalist Neurologist Neurologist Acute stroke clinician/neurologist who Professor of Neurology at The University of Dr Saver is Professor and Senior has previous experience initiat
Slide 18: Traumatic Brain Injury Update
TRAUMATIC BRAIN INJURY UPDATE PROGRESS TOWARDS PHASE 1B TRIAL IN MODERATE TO SEVERE TBI ESTABLISHING PARTNERSHIPS WITH LEADING AUSTRALIAN INSTITUTIONS Argenica is in the final stages of engaging a number of hospital and academic institutions to establish collaboration agreements to execute the Phase
Slide 19: Potential Catalysts for 2026
POTENTIAL CATALYSTS FOR 2026 Complete responses to IND Clinical Hold H2 US IND Approval for ARG-007 in Stroke 2026 HREC Approval for ARG-007 in Stroke Completion of large-scale manufacturing of clinical trial batches for clinical trials in stroke and TBI Stroke Phase 2b Trial Site identifi
Slide 20: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 20 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (June 2026) on 6ix